DMK PHARMACEUTICALS CORP (DMK) Stock Fundamental Analysis

NASDAQ:DMK • US00547W3079

0.232 USD
+0 (+0.91%)
At close: Feb 6, 2024
0.1665 USD
-0.07 (-28.23%)
After Hours: 2/6/2024, 8:05:16 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DMK. DMK was compared to 191 industry peers in the Pharmaceuticals industry. DMK may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, DMK is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year DMK has reported negative net income.
  • In the past year DMK has reported a negative cash flow from operations.
DMK Yearly Net Income VS EBIT VS OCF VS FCFDMK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

  • DMK's Return On Assets of -248.15% is on the low side compared to the rest of the industry. DMK is outperformed by 93.56% of its industry peers.
Industry RankSector Rank
ROA -248.15%
ROE N/A
ROIC N/A
ROA(3y)-173.97%
ROA(5y)-129.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DMK Yearly ROA, ROE, ROICDMK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 1K -1K 2K 3K 4K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for DMK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMK Yearly Profit, Operating, Gross MarginsDMK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • DMK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • DMK has about the same amout of shares outstanding than it did 1 year ago.
  • There is no outstanding debt for DMK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DMK Yearly Shares OutstandingDMK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M
DMK Yearly Total Debt VS Total AssetsDMK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

  • DMK has an Altman-Z score of -60.09. This is a bad value and indicates that DMK is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -60.09, DMK is doing worse than 94.55% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -60.09
ROIC/WACCN/A
WACC8.88%
DMK Yearly LT Debt VS Equity VS FCFDMK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 0.58 indicates that DMK may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.58, DMK is doing worse than 92.57% of the companies in the same industry.
  • A Quick Ratio of 0.54 indicates that DMK may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.54, DMK is doing worse than 93.07% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.58
Quick Ratio 0.54
DMK Yearly Current Assets VS Current LiabilitesDMK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • DMK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.96%, which is quite impressive.
  • Looking at the last year, DMK shows a very strong growth in Revenue. The Revenue has grown by 160.36%.
  • DMK shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.29% yearly.
EPS 1Y (TTM)37.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.73%
Revenue 1Y (TTM)160.36%
Revenue growth 3Y-40.07%
Revenue growth 5Y-18.29%
Sales Q2Q%-99.4%

3.2 Future

  • Based on estimates for the next years, DMK will show a very strong growth in Earnings Per Share. The EPS will grow by 25.25% on average per year.
  • Based on estimates for the next years, DMK will show a very strong growth in Revenue. The Revenue will grow by 53.75% on average per year.
EPS Next Y64.16%
EPS Next 2Y38.62%
EPS Next 3Y25.25%
EPS Next 5YN/A
Revenue Next Year-68.82%
Revenue Next 2Y-0.76%
Revenue Next 3Y53.75%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DMK Yearly Revenue VS EstimatesDMK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
DMK Yearly EPS VS EstimatesDMK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2023 2024 2025 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • DMK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year DMK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DMK Price Earnings VS Forward Price EarningsDMK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMK Per share dataDMK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as DMK's earnings are expected to grow with 25.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.62%
EPS Next 3Y25.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for DMK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

DMK PHARMACEUTICALS CORP

NASDAQ:DMK (2/6/2024, 8:05:16 PM)

After market: 0.1665 -0.07 (-28.23%)

0.232

+0 (+0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14
Earnings (Next)03-14
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.09%
Ins Owner Change0%
Market Cap2.34M
Revenue(TTM)3.62M
Net Income(TTM)-22.23M
Analysts80
Price Target1.53 (559.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.65
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-9.17
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS0.36
BVpS-0.49
TBVpS-0.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -248.15%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-173.97%
ROA(5y)-129.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.2%
Cap/Sales 2.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.58
Quick Ratio 0.54
Altman-Z -60.09
F-Score5
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)52.33%
Cap/Depr(5y)73.76%
Cap/Sales(3y)34.55%
Cap/Sales(5y)28.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.73%
EPS Next Y64.16%
EPS Next 2Y38.62%
EPS Next 3Y25.25%
EPS Next 5YN/A
Revenue 1Y (TTM)160.36%
Revenue growth 3Y-40.07%
Revenue growth 5Y-18.29%
Sales Q2Q%-99.4%
Revenue Next Year-68.82%
Revenue Next 2Y-0.76%
Revenue Next 3Y53.75%
Revenue Next 5YN/A
EBIT growth 1Y12.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y74.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.31%
OCF growth 3YN/A
OCF growth 5YN/A

DMK PHARMACEUTICALS CORP / DMK FAQ

Can you provide the ChartMill fundamental rating for DMK PHARMACEUTICALS CORP?

ChartMill assigns a fundamental rating of 2 / 10 to DMK.


What is the valuation status for DMK stock?

ChartMill assigns a valuation rating of 1 / 10 to DMK PHARMACEUTICALS CORP (DMK). This can be considered as Overvalued.


How profitable is DMK PHARMACEUTICALS CORP (DMK) stock?

DMK PHARMACEUTICALS CORP (DMK) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for DMK stock?

The Earnings per Share (EPS) of DMK PHARMACEUTICALS CORP (DMK) is expected to grow by 64.16% in the next year.